2.30

8.37% -0.21

Pre-market: 2.30

Bioaffinity Technologies Inc (BIAF)

Overview News Price History Financials Discussions Forecast

Bioaffinity Technologies Inc stock is traded at $2.30, with a volume of 186.38K. It is down -8.37% in the last 24 hours and down -51.37% over the past month. bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Previous Close:

$2.51

Open:

$2.5

24h Volume:

186.38K

Relative Volume:

0.02

Market Cap:

$10.35M

Revenue:

$6.16M

Net Income/Loss:

$-14.91M

P/E Ratio:

-0.2156

EPS:

-10.6693

Net Cash Flow:

$-9.39M

1W Performance:

-16.67%

1M Performance:

-51.37%

6M Performance:

-12.88%

1Y Performance:

-84.50%

1-Day Range:

$2.22

$2.50

1-Week Range:

$2.22

$2.90

52-Week Range:

$0.693

$15.89

Bioaffinity Technologies Inc Stock (BIAF) Company Profile

Name

Bioaffinity Technologies Inc

Sector

Healthcare (1111)

Industry

Diagnostics & Research (52)

Phone

210-698-5334

Address

3300 NACOGDOCHES ROAD, SAN ANTONIO

Employee

Twitter

Next Earnings Date

2026-05-21

Latest SEC Filings

BIAF's Discussions on Twitter

Compare BIAF vs TMO, DHR, IDXX, A, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BIAF Bioaffinity Technologies Inc	2.30	11.74M	6.16M	-14.91M	-9.39M	-10.67
TMO Thermo Fisher Scientific Inc	466.70	194.94B	44.56B	6.72B	6.29B	17.74
DHR Danaher Corp	178.57	137.69B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	560.93	45.19B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	114.42	34.50B	7.07B	1.29B	993.00M	4.5355
WAT Waters Corp	311.20	32.91B	3.17B	642.63M	516.49M	10.77

Bioaffinity Technologies Inc Stock (BIAF) Latest News

Apr 23, 2026

BioAffinity stock surges 113.8% in 3 months: What's driving the rally? - MSN

Apr 23, 2026

Apr 22, 2026

bioAffinity Technologies Working With U.S. Army on CyPath Lung Study - Medical Product Outsourcing

Apr 22, 2026

Apr 20, 2026

BioAffinity (BIAF) Stock in Focus Today (Volatility Increases) 2026-04-20Trading Community - Cổng thông tin điện tử tỉnh Lào Cai

Apr 20, 2026

Apr 18, 2026

BioAffinity shares rise as CyPath Lung growth boosts optimism - MSN

Apr 18, 2026

Apr 16, 2026

BioAffinity (BIAF) Stock Slides (Breakdown Watch) 2026-04-16Shared Momentum Picks - Cổng thông tin điện tử Tỉnh Sơn La

Apr 16, 2026

bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally? - The Globe and Mail

Apr 16, 2026

Apr 15, 2026

New Case Study Shows bioAffinity Technologies CyPath Lung Diagnostic Helps Avoid Unnecessary Lung Biopsy - National Today

Apr 15, 2026

CyPath® Lung Diagnostic Helps Defer Unnecessary Biopsy - National Today

Apr 15, 2026

New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy - BioSpace

Apr 15, 2026

Apr 14, 2026

New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, P - PharmiWeb.com

Apr 14, 2026

bioAffinity Highlights CyPath Lung Case Avoiding Unnecessary Biopsy - TipRanks

Apr 14, 2026

CyPath Lung case study at bioAffinity (NASDAQ: BIAF) shows biopsy deferred - Stock Titan

Apr 14, 2026

UGRO, TURB, ANNA, EEIQ, BIAF: These five stocks outpaced big tech with massive March returns - MSN

Apr 14, 2026

Apr 13, 2026

Institution Moves: Can bioAffinity Technologies Inc lead its sector in growth2026 Trading Volume Trends & Weekly Watchlist of Top Performers - baoquankhu1.vn

Apr 13, 2026

Investment Review: Is bioAffinity Technologies Inc Equity Warrant stock overvalued or fairly priced2026 Buyback Activity & Technical Pattern Based Buy Signals - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

BIAF PE Ratio & Valuation, Is BIAF Overvalued - Intellectia AI

Apr 12, 2026

Apr 10, 2026

Wall Street Recap: Can bioAffinity Technologies Inc Equity Warrant outperform under higher oil pricesMarket Performance Report & Low Drawdown Investment Ideas - baoquankhu1.vn

Apr 10, 2026

Jobs Data: What hedge funds are buying bioAffinity Technologies Inc Equity WarrantWeekly Trading Summary & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn

Apr 10, 2026

What is the volatility of BioAffinity (BIAF) Stock | Price at $3.54, Up 6.66%Money Flow - Cổng thông tin điện tử tỉnh Lào Cai

Apr 10, 2026

Apr 09, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Apr 09, 2026

Apr 07, 2026

bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early - PharmiWeb.com

Apr 07, 2026

bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16 - BioSpace

Apr 07, 2026

bioAffinity Showcases CyPath Lung Test at Cleveland Clinic - TipRanks

Apr 07, 2026

CyPath Lung spotlight for bioAffinity Technologies (Nasdaq: BIAF) - Stock Titan

Apr 07, 2026

Apr 06, 2026

Risk Analysis: What are the future prospects of bioAffinity Technologies Inc Equity Warrant2026 Trading Recap & Community Consensus Trade Signals - baoquankhu1.vn

Apr 06, 2026

Is BioAffinity (BIAF) Stock Showing Strength | Price at $3.88, Down 1.02%Community Buy Signals - UBND thành phố Hải Phòng

Apr 06, 2026

Apr 04, 2026

bioAffinity reports 146% jump in Q1 lung test sales By Investing.com - Investing.com South Africa

Apr 02, 2026

BIAF stock gains as CyPath sales surge 146% in Q1 - MSN

Apr 02, 2026

bioAffinity Technologies’ CyPath® Lung Test Sales Surge 146% in Q1 2026, Driven by Growing Adoption for Early Lung Cancer Detection 1 - Minichart

Apr 02, 2026

Apr 01, 2026